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1. Introduction 
Osteosarcoma has been recognized for almost two centuries and is the most common 
primary, non-haemopoietic malignant tumour of the skeletal system. It is thought to arise 
from primitive mesenchymal bone-forming cells and its histologic hallmark is the 
production of osteoid. Other cell populations may also be present, as these types of cells 
may also arise from pluripotential mesenchymal cells, but any area of bone or osteoid 
synthesized by malignant cells in the lesion establishes the diagnosis of osteosarcoma 
(Acchiappati et al, 1965). 
It accounts for approximately 20% of all primary malignant bone tumours. In the United 
States, the incidence of osteosarcoma is 400 cases per year (4.8 per million population <20 y). 
The incidence is slightly higher in blacks than in whites (Huvos et al, 1983), in males than in 
females. It has a bimodal age distribution and a propensity to develop in adolescents and 
young adults (Dix et al, 1983; Soloviev, 1969; Wilimas, et al, 1977, Dorfman & Czerniak, 
1995), with 60% of tumours occurring in patients younger than 25 years of age and only 13% 
to 30% in patients older than 40 years (de Santos et al, 1982; Huvos, 1986). Osteosarcoma is 
very rare in young children (0.5 cases per million per year in children <5y). 
Osteosarcoma can occur in any bone, but most tumours originate in the long bones of the 
appendicular skeleton, near metaphyseal growth plates, especially the distal femur (42%, 75% 
of which in the distal femur), followed by the proximal tibia (19%, 80% of which in the 
proximal tibia) and proximal humerus (10%, 90% of which in the proximal humerus) (Goes M, 
1952). In the long bones the tumour is most frequently centered in the metaphysis (90%), 
infrequently in the diaphysis (9%) and rarely in the epiphysis (Tsuneyoshi & Dorfman, 1987). 
Other significant locations are the skull and jaw (8%) and pelvis (8%) (Benson et al, 1984).  
The clinicopathologic features of osteosarcoma form the basis of its classification, most 
importantly including the histologic features, the biologic potential (grade), relation to bone 
(intramedullary or surface), multiplicity (solitary and multifocal) and the pre-existing state 
of underlying bone (primary or secondary).  
Osteosarcomas have a wide range of radiographic and histologic appearances. For example, 
some may be radiolucent or radiodense. Some are confined to the medullary cavity, or 
originate and grow on the bone surface. Some arise on normal bone (de novo osteosarcoma), 
others arise in the setting of Paget disease or radiation (secondary osteosarcoma). Most arise 
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in genetically normal individuals but rare cases have been seen in patients’ various genetic 
syndromes (such as Rothmund-Thompson, Li Fraumeni and Retinoblastoma gene mutation) 
(Dick et al, 1982; Hansen et al, 1985; Kozlowski et al, 1980). The vast majority are solitary 
lesions, although rare cases of multifocal osteosarcomas have been reported (Ackermann, 
1948, Amstutz, 1969, Laurent et al, 1973).  
According to the mode of growth, osteosarcomas are subdivided into intramedullary and 
surface osteosarcomas. Intramedullary osteosarcomas are further subdivided into typical 
intramedullary, telangiectatic and highly differentiated. Surface osteosarcomas are subdivided 
into periosteal and parosteal osteosarcomas and high-grade surface osteosarcomas. According 
to the prevalent cell in the neoplastic tissue are subdivided into osteoblastic, chondroblastic, 
fibroblastic, giant cell, small cell and mixed (McDonald & Budd, 1943). 
Most osteosarcomas can be categorized into four major groups: 1) conventional, high grade 
osteosarcoma and its histologic subtypes (75%-85%), 2) high grade osteosarcoma that arises 
in a diseased bone (10%), 3) intramedullary, well-differentiated (1%) and 4) surface 
osteosarcoma (5%-10%).  
Bone tumour grading has traditionally been based on a combination of histologic diagnosis 
and the Broders grading system which assesses cellularity and degree of anaplasia (Broders, 
1920; Inwards & Unni, 1995). The 7th edition of the AJCC Cancer Staging Manual 
recommends a 4-grade system (Edge et al, 2009), with grades 1 and 2, considered as ‘low 
grade’ and grades 3 and 4 ‘high grade’. The 2009 CAP Bone Tumour Protocol recommends a 
pragmatic approach, based principally on histologic classification. Under this system, 
central low grade osteosarcoma and parosteal osteosarcoma are considered Grade 1 
sarcomas, with periosteal osteosarcoma considered Grade 2, and all other osteosarcomas 
considered Grade 3 (Dorfman et al, 1998, 2002).  
The exact cause of osteosarcoma is unknown. The best known causative association -
environmental risk factor is exposure to radiation (Huvos, 1986). Its causal relation was first 
documented in radium dial painters. Osteosarcoma after therapeutic irradiation is an 
uncommon complication, and usually develops after approximately 15 (range 3 to 55) years. 
Osteosarcoma is known to affect approximately 1% of patients with Paget disease of bone, 
which reflects a several thousand-fold increase in risk in comparison with that of the general 
population (Wick et al, 1981).  
Osteosarcoma may also arise in sites of previous bone infarction (Mirra et al, 1974), chronic 
osteomyelitis (Bartkowski & Klenczynski, 1974; Spyra, 1976), pre-existing primary benign 
bone tumours (osteochondroma, enchondroma, fibrous dysplasia, giant cell tumour, 
osteoblastoma, aneurysmal bone cyst and unicameral bone cyst) and adjacent to metallic 
implants (Johnson et al, 1962; Koppers et al, 1977, Ruggieri 1995; Schweitzer & Pirie, 1971; 
Smith et al, 1986). These secondary osteosarcomas account for only a small percentage of 
osteosarcomas and their pathogenesis is likely related to chronic cell turnover that is 
associated to the underlying bone disease. 
The diagnosis of osteosarcoma, like all bone-tumours, emphasizes the necessity of close 
cooperation of all involved disciplines for diagnosis and therapy, including clinicians, 
radiologists and pathologists, as the correct diagnosis relies on their clinico-pathological 
appearance. 
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2. Pathologic features 
2.1 Conventional osteosarcoma 
Conventional osteosarcoma, is solitary, arises in the medullary cavity of an otherwise 
normal bone, is of high grade and produces neoplastic bone with or without cartilaginous or 
fibroblastic components. The gross findings are variable depending on the amount of bone 
and other components present. It manifests as a large, metaphyseal, intramedullary and tan-
gray-white, gritty mass. Tumours that are producing abundant mineralized bone are tan-
gray and hard, whereas non-mineralized, cartilaginous components are glistening, gray, and 
may be mucinous if the matrix is myxoid, or more rubbery if hyaline in nature. It can be 
necrotic, hemorrhagic and cystic. Intramedullary involvement is often considerable and the 
tumour usually destroys the overlying cortex and forms an eccentric or circumferential soft 
tissue component that displaces the periosteum peripherally. In the proximal and distal 
portions of the tumour the raised periosteum deposits a reactive bone, known as Codman’s 
triangle. In some cases, the tumour grows into the joint space, resulting in coating of the 
peripheral portions of the articular cartilage by the sarcoma. Solitary or multiple skip 
metastases appear as intramedullary nodules in the vicinity of or far from the main mass. 
Furthermore, not all osteosarcomas arise in a solitary fashion, as multiple sites may become 
apparent within a period of about 6 months (synchronous osteosarcoma), or multiple sites 
may be noted over a period longer than 6 months (metachronous osteosarcoma). Such 
multifocal osteosarcoma is decidedly rare, but when it occurs, it tends to be in patients, 
younger than 10 years. 
The diagnosis of osteosarcoma is based on the accurate identification of osteoid. Osteoid is 
unmineralized bone matrix that histologically appears as eosinophilic, dense, homogeneous, 
amorphous and curvilinear intercellular material, somewhat refractile. It must be 
distinguished from other eosinophilic extra-cellular materials such as fibrin and amyloid. 
Unequivocal discrimination between osteoid and non-osseous collagen may be difficult, or 
sometimes arbitrary (Fornasier, 1977). Non-osseous collagen tends to be linear, fibrillar and 
compresses between neoplastic cells. In contrast, osteoid is curvilinear with small nubs, 
arborisation and what appears to be abortive, lacunae formation. The thickness of the 
osteoid is highly variable with the ‘thinnest’ variant referred to as ‘filigree’, whereas osteoid 
seams are flat and thick. Osseous matrix has also the predisposition for appositional 
deposition upon previously existing normal bone trabeculae (‘scaffolding’).  
Conventional osteosarcoma can produce varying amounts of cartilage and/or fibrous tissue. 
The algorithm is: identify the presence or absence of matrix, and if significant matrix is 
present, determine the matrix form and therefore subclassify into osteoblastic, 
chondroblastic, fibroblastic and mixed types, by virtue of the predominance of the 
neoplastic component. 
Histologic subtyping may not always be possible, even with generous sampling. Such lesions 
are better categorized under the term ‘osteogenic sarcoma with no predominant growth 
pattern’. Furthermore, sub-classification on local recurrence or following chemotherapy or 
irradiation can provide false results, because treatment can alter tumour appearance. 
In addition, osteosarcoma may be of any histologic grade. Some contain highly pleomorphic 
cells and abundant mitotic figures, whereas others may be difficult to differentiate from 
benign neoplasms. 
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2.1.1 Osteoblastic osteosarcoma 
Conventional osteosarcoma is usually of the osteoblastic type. In osteoblastic osteosarcoma 
the predominant matrix is bone and/or osteoid. It contains pleomorphic malignant cells and 
coarse neoplastic woven bone. The tumour cells are intimately related to the surface of the 
neoplastic bone, which is woven in architecture, varies in quantity and is deposited as 
primitive, disorganized trabeculae in a coarse, lace-like pattern, thin, arborising lines of 
osteoid (filigree) interweaving between neoplastic cells, or broad, large sheets of coalescing , 
trabeculae, as seen in the sclerosing variant. Depending on its state of mineralization, the 
bone can be eosinophilic, or basophilic and may have a pagetoid appearance caused by 
haphazardly deposited cement lines. 
2.1.2 Chondroblastic osteosarcoma 
Chondroid matrix is predominant in chondroblastic osteosarcoma, intimately associated 
with non-chondroid elements. The neoplastic chondrocytes are mostly characterized by 
severe cytologic atypia and reside in lacunar spaces, hyaline matrix or float singly or in 
cords in myxoid matrix. Myxoid and other forms of cartilage are uncommon, except in the 
jaws and in the pelvis. 
2.1.3 Fibroblastic osteosarcoma 
Typically, is composed of fusiform highly pleomorphic malignant cells, arranged in a 
herringbone or storiform pattern, similar to fibrosarcoma or malignant fibrous histiocytoma, 
with minimal osseous matrix. Although, the degree of atypia is variable, is frequently 
severe, with numerous mitoses, including atypical forms. In general, the lack of significant 
amounts of osteoid, bone or cartilage, relegates them to subtypes of fibroblastic 
osteosarcoma. 
Although, there is a tendency for metastases of osteosarcomas to mimic the primary, 
exceptions are frequent and is a higher than expected incidence of fibroblastic differentiation 
in metastases. 
2.2 Small cell osteosarcoma 
It comprises 1.5% of osteosarcomas, with slight predilection for females and is composed of 
small cells with variable degree of osteoid production (Sim et al, 1979). According to the 
predominant cell pattern, tumours are classified to round cell type or short spindle cell type. 
Nuclei can be very small to medium sized, with scanty amount of cytoplasm, comparable to 
those of Ewing sarcoma and to large cell lymphoma respectively. The chromatin 
distribution can be fine or coarse and the mitoses range from 3 to 5/per high power field-
HPF. Lace-like osteoid production is always present, although particular care must be taken 
to differentiate osteoid from fibrin deposits that may be seen among Ewing sarcoma cells. 
2.3 Telangiectatic osteosarcoma 
When first recognized, telangiectatic osteosarcoma was considered a distinct clinical and 
pathologic entity (Gaylord, 1903). On the basis of subsequent findings, telangiectatic 
osteosarcoma was considered a variant of osteosarcoma (Ewing, 1922, 1939).  
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It is rare, less than 4% of all cases of osteosarcomas and more frequent in the second decade 
of life. Although, most frequently affects long tubular bones, has also been noted to arise in 
extraosseous soft tissues in the forearm, thigh and popliteal fossa (Mirra et al, 1993). 
Radiographically, is characterized by typically purely lytic destructive process, without 
matrix mineralization. Clinically, a pathological fracture is present in one fourth of the cases. 
On gross examination, there is a dominant cystic architecture in the bone medulla. The 
cystic space is filled incompletely with blood clot, described as ‘a bag of blood’. 
Histologically, the tumour is characterized by dilated, blood-filled or empty spaces, 
separated by thin septae, simulating aneurysmal bone cyst. The cystic spaces are lined by 
benign osteoclast-like giant cells, without endothelial lining. The septae are cellular, 
containing highly malignant, atypical mononuclear tumour cells with high mitotic activity, 
including atypical mitoses. The amount of osteoid varies, but usually is fine, lace-like and of 
minimal amount, although it tends to be more prominent in metastatic foci. Therefore, it is 
imperative that the entire specimen is meticulously examined histologically. 
Telangiectatic osteosarcomatous differentiation has been reported in parosteal 
osteosarcoma (Wines et al,2000), in dedifferentiated chondrosarcoma arising in the 
background of osteochondroma (Radhi & Loewy, 1999), in association with aneurysmal 
bone cysts (Adler, 1980; Kyriakos & Hardy, 1991), in osteitis deformans, as well as in cases 
of malignant phylloedes tumour of the breast (Gradt et al, 1998) and in ovarian sarcomas 
(Hirakawa et al, 1998). 
2.4 Low grade central (well differentiated intraosseous/intramedullary) osteosarcoma 
It accounts for 1-2% of all osteosarcomas and is the medullary equivalent to parosteal 
osteosarcoma (Kurt et al, 1990; Unni et al, 1977). There is a tendency for a slightly older age 
and slightly longer symptomatology in comparison to the conventional osteosarcoma. It is 
important to recognize this subtype, since the patient tends to do much better, than those 
with conventional osteosarcoma. It is a low grade fibroblastic osteosarcoma and is 
histologically identical to parosteal osteosarcoma. 
Histologically, contains long, parallel trabeculae or round islands of woven bone intimately 
associated with a mildly to moderately cellular population of cytologically bland neoplastic 
spindle cells with variable amounts of osteoid production. Nuclear enlargement and 
hyperchromasia are generally evident with occasional mitotic figures (1-2 mitoses per 10 
high power fields-HPFs). When involving the medullary canal it may be confused with 
fibrous dysplasia (FD). Radiologically, FD is homogeneous (‘ground glass’ appearance), 
whereas the well differentiated osteosarcoma is less so, and may show trabeculations. 
Furthermore, a permeative growth pattern into the pre-existing lamellar bone or fatty 
marrow is diagnostic. Microscopically, the trabeculae of FD tend to be rather short and 
curled, whereas those of well differentiated osteosarcoma are longer and may be arranged 
in parallel arrays. Again, cytologic atypia should be sought and is diagnostic if found. 
Conventional osteosarcomas often have better differentiated, innocuous ‘normalized’ areas. 
These should not be underdiagnosed as low grade osteosarcoma, since biologically they 
behave accordingly to their more aggressive foci. 
Desmoplastic fibromas may infiltrate the bone and can be diagnostically challenging. In 
these cases, osteoid production should be sought. Radiographic evidence of matrix 
production is helpful in establishing the correct diagnosis. 
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Fig. 1. (A-D) Intramedullary (central)  low grade osteosarcoma (H&E stain). A. Long 
parallel neoplastic bony trabeculae associated with spindle cell stroma. B. Hypocellular 
spindle cell collagenized stroma with osteoid production C. Scattered fusiform cells with 
nuclear enlargement (high magnification). D. Area of chondroblastic differentiation. (E, F) 
Osteosarcoma fibroblastic type (H&E stain). E. Neoplastic bony trabeculae surrounded by 
spindle cell stroma exhibiting scattered cytologic atypia prominent at low magnification. F. 
Prominent cytologic atypia (high magnification) 
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Fig. 2. (A, B) Telangiectatic osteosarcoma (H&E stain). (A) Blood-filled cystic spaces, 
separated by septae with abundant osteoclastic-type giant cells. (B) Giant cell-rich area with 
high cellular pleomorphism and patchy osteoid formation. (C-E) Extraskeletal osteosarcoma 
of the breast. (C) Well circumscribed margins, peripheral spindle cell component and 
chondroblastic area (on the right). (D) Highy pleomorphic tumor cells including mitoses. (E) 
Osteoblastic osteosarcoma area with abundant mineralized osteoid. (F) Fine needle aspirate 
from extraskeletal osteosarcoma of the breast (MGG stain). Cellular smear displaying 
epithelioid cells with plasmacytoid appearance. (Inset) Enlarged pleomorphic cell with fine 
cytoplasmic vacuolization, reminiscent of neoplastic chondroblast in association with red-
purple amorphous material (reproduced with permission from S. Karger A.G., Medical and 
Scientific Publishers, first published by Trihia  et al, Acta Cytologica, 2007;51:443-450) 
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2.5 Secondary osteosarcomas 
Secondary osteosarcomas are bone forming sarcomas occurring in bones that are affected by 
preexisting abnormalities, the most common being Paget disease and radiation change. 
2.5.1 Paget osteosarcoma 
Incidence of sarcomatous change in Paget disease is estimated to 0.7-0.95%, with 
osteosarcomas representing 50-60% of Paget sarcomas (Haibach et al, 1985; Huvos et al, 
1983; Schajowicz et al, 1983). It is more common in men, with median age of 64 years and is 
usually observed in patients with widespread Paget disease (70%). Most tumours arise in 
the medulla. Histologically are high grade sarcomas, mostly osteoblastic or fibroblastic. A 
great number of osteoclast-like giant cells may be found. Telangiectatic and small cell 
osteosarcomas have been reported. 
2.5.2 Post-radiation osteosarcoma 
They constitute 3.4-5.5% of all osteosarcomas and 50-60% of radiation-induced sarcomas. It is 
estimated that the risk of developing osteosarcoma in irradiated bone is 0.03-0.8% (Huvos et al, 
1985; Mark et al, 1994). Children treated with high-dose radiotherapy and chemotherapy are at 
the greater risk, and the prevalence of post-radiation osteosarcomas is increasing as children 
survive treatment for their malignant tumour. It can develop in any irradiated bone, with most 
common locations the pelvis and the shoulder. The modified criteria for postradiation cancer 
initially promulgated in 1948 by Cahan and associates are as follows : (1) the patient received 
irradiation, (2) the neoplasm occurred in the radiation field, (3) a latent period of years had 
elapsed, (4) histologic or radiographic evidence for the pre-existent osseous lesion, a benign 
tumour or non-bone forming malignancy (Cahan et al, 1948). 
Histologically, high grade osteosarcomas predominate. 
Many of the reported cases of osteosarcoma arising in fibrous dysplasia have also been 
complicated by radiation therapy.  
2.5.3 Osteosarcomas in other benign precursors 
Other rare instances of secondary osteosarcomas have included cases arising in association 
with bone infarcts, endoprostheses and already mentioned fibrous dysplasia. Infarct 
associated sarcomas as well as malignant tumours at the site of prosthetic replacements 
(Brien et al, 1990), or at the site of prior fixation, most commonly show the histological 
pattern of malignant fibrous histiocytoma (MFH), with a minority being osteosarcomas. 
2.6 Parosteal osteosarcoma 
It is the most common type of osteosarcoma of the bone surface, although it accounts for 
about 5% of all osteosarcomas, with a slight female predominance (Okada et al, 1995). It is a 
low grade, slow growing neoplasm, with a predilection for the posterior aspect of the distal 
femur, where presents as a hard lobulated mass attached to the underlying cortex with a 
broad base. Histologically, it is a well differentiated fibro-osseous neoplasm, consisting of 
well formed bony trabeculae embedded in a hypocellular fibrous stroma. The bony 
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trabeculae can be arranged in parallel strands, simulating normal bone and may or may not 
show osteoblastic rimming. The intertrabecular stroma is hypocellular with minimal atypia, 
whereas it can be more cellular with moderate cytologic atypia in 20% of cases. About 50% 
of the tumours will show cartilaginous differentiation, in the form of hypercellular nodules 
of cartilage within the tumour substance or as a cup on the surface. When present, the 
cartilage cup is mildly cellular with mild cytologic atypia and lacks the ‘columnar’ 
appearance seen in osteochondromas. 
About 15% of the tumours will show high grade spindle cell sarcoma (dedifferentiation), 
more often at the time of recurrence, in the form of osteosarcoma, fibrosarcoma or MFH 
(Wold et al, 1984). 
Its diagnosis can be very difficult and the differential diagnosis has included diverse 
entities, such as: myositis ossificans, fracture callus, ossifying haematoma, osteochondroma, 
extraosseous osteosarcoma, parosteal chondroma, desmoplastic fibroma and osteoma. 
Therefore, parosteal osteosarcoma, like no other tumour, implies the necessity of close 
cooperation of all involved disciplines for the correct diagnosis. 
2.7 Periosteal osteosarcoma  
It accounts for less than 2% of all osteosarcomas, more common than high grade surface 
osteosarcoma, but about one third as common as parosteal osteosarcoma (Unni et al, 1976). 
Unlike parosteal osteosarcoma, which extends from the cortex like a bony knob, periosteal 
osteosarcoma tightly encases the bone, like a glove. Unlike other osteosarcomas, it tends to 
involve the diaphysis. Radiologically, it is a circumferential surface mass, less radiodense 
than parosteal osteosarcoma. Mineralization occurs as ring-shaped radiodensities or as 
streaks of reactive bone radiating from the surface. Lesions can be best visualized by MRI 
scan. A sub-periosteal lesion with a bright white signal is present, indicating its high 
cartilage content. Histologically, it has the appearance of a moderately differentiated, grade 
2/3 chondroblastic osteosarcoma. It consists almost entirely of lobules of cellular, atypical 
cartilage, with bone formation in the centre of the lobules, separated by thin strands of 
fibrous tissue. Careful scrutiny of the fibrous component, reveals seams of neoplastic 
osteoid, usually at the outer surface of the neoplasm, which distinguishes it from surface 
chondrosarcoma. 
2.8 High grade surface osteosarcoma 
A high grade, bone-forming malignant tumour, arising from the bone surface, which 
comprises less than 1% of all osteosarcomas. Histologically, is similar to conventional 
osteosarcoma. Regions of predominantly osteoblastic, chondroblastic, or fibroblastic 
differentiation may predominate. However all tumours will show high cytologic atypia and 
lace-like osteoid. The pattern of osteoid production and the high grade cytologic atypia help 
to separate it from parosteal osteosarcoma. High grade surface osteosarcoma with 
chondroblastic differentiation may be confused with periosteal osteosarcoma. The degree of 
cytologic atypia is greater in high grade surface osteosarcoma and the tumours generally 
show larger spindle cell areas. Finally, unlike dedifferentiated parosteal osteosarcomas, low 
grade regions are not found in high grade surface osteosarcomas. 
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Cortical destruction and invasion into the medullary canal in high-grade juxtacortical 
(periosteal and high-grade surface) osteosarcomas, is often absent, but when present, is only 
focal. If extensive, it becomes difficult, if not impossible to distinguish an intramedullary 
tumour with an eccentric soft tissue component from a surface neoplasm with extensive 
invasion of the medullary canal. 
2.9 Extraskeletal osteosarcomas  
Extraskeletal osteosarcomas (EOs) or soft tissue osteosarcomas (STOs) are rare sarcomas 
arising in extraskeletal somatic soft tissue, in which the neoplastic cells produce osteoid 
and/or bone matrix, therefore recapitulating the phenotype of osteoblasts. By definition, it is 
a high grade mesenchymal neoplasm that produces osteoid, bone and chondroid material, 
shows no evidence of epithelial component and is located in soft tissues, without attachment 
to bone or periosteum, as determined by X-ray findings or inspection during the operative 
procedure. It is significantly less frequent than its osseous counterpart. They account for 
1.2% of soft tissue sarcomas and 4% of osteosarcomas (Bane et al, 1990; Sordillo et al, 1983). 
They typically arise in the deep soft tissues of the proximal extremities, with most common 
locations the deep soft tissues of the thigh and buttocks, followed in descending order by 
the upper limb, retroperitoneum, trunk, head and neck (Chung & Enzinger, 1987; Lee et al, 
1995; Lidang et al, 1998; Sordillo et al, 1983). Fewer than 10% are superficial, originating in 
the dermis or subcutis. Cases of EOs arising in unusual sites have been reported, such as the 
breast, larynx, thyroid gland, parotid, abdominal viscera, including esophagus, small 
intestine, omentum majum, liver, heart, the urogenital system, including urinary bladder, 
ureter the prostate and the penis, pleura, mediastinum, ectopic thymus, pulmonary artery, 
pilonidal area and aorta (Baydar, et al, 2009; Burke & Virmani, 1991; Kemmer et al, 2008; 
Loose et al, 1990; Micolonghi et al, 1984; Piscioli et al, 1985; Shui et al, 2011; Silver & 
Tavassoli, 1998; Trowell & Arkell, 1976; Young & Rosenberg, 1987; Wegner et al, 2010; 
Greenwood & Meschter, 1989). Fewer than 300 cases have been reported to date and their 
aetiology is essentially unknown. Unlike osseous conventional osteosarcoma, it typically 
occurs in older adults, with a peak incidence in the fifth and sixth decades of life, in contrast 
with skeletal osteosarcomas that most commonly affect young adults (Sordillo et al, 1983). 
Males are affected more frequently than females at a ratio of 1.9:1. Some cases have been 
associated with a history of prior therapeutic irradiation at the site of the tumour (Logue & 
Cairnduff, 1991) and trauma (Allan & Soule, 1971). In one case report of primary 
osteosarcoma of the urinary bladder, prolonged treatment with immunosuppressive 
medications, including cyclophosphamide for active systemic lupus erythematosus (SLE) 
has been reported (Baydar et al, 2009). The diagnosis is generally delayed and prognosis is 
poor, with most patients died within months of diagnosis and with a cause-specific survival 
rate at 5 years less than 25%. Clinically and mammographically can mimic a benign tumour. 
Like most of soft tissue sarcomas, tumours may appear grossly circumscribed, however they 
are microscopically infiltrative. Imaging studies usually reveal compact 
calcifications/variable mineralization within the mass. Primary extraosseous osteosarcoma 
should always be included in the differential diagnosis, in the view of a well demarcated 
calcified mass on image analysis. In the case of extraskeletal osteosarcoma of the breast, an 
underdiagnosis as a calcified fibroadenoma, should be avoided. 
STOs are usually large, ranging in size between 5 and 10 cm, well-circumscribed, grossly 
heterogeneous tumours that exhibit areas of haemorrhage and/or necrosis. Microscopically, 
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STOs constitute highly cellular, cytologically pleomorphic, mitotically active sarcomas, spindle 
cell to epithelioid in appearance. The defining feature is the presence of neoplastic osteoid 
and/or bone. The latter usually presents in a ‘lace like’ manner, although solid sheets of 
amorphous osteoid can also be found. When the bone/osteoid matrix is found only focally in 
the tumour, largely demonstrates a nonspecific, undifferentiated, spindle cell sarcomatous 
appearance. Lobules of highly cellular, atypical hyaline/fibrocartilage may also present. 
Osteoclast-like giant cells have also been described. Various histologic subtypes of bone 
osteosarcoma can be seen in extraskeletal osteosarcoma. Osteoblastic variant is the most 
common type, followed by fibroblastic, chondroid, telangiectatic, small cell and well-
differentiated variants. Common to all variants is the production of osteoid, intimately 
associated with tumour cells, which may be deposited in a lacy, trabecular or sheet-like 
pattern. Neoplastic bone formation is more prominent in the centre of the tumour with the 
peripheral areas being more cellular, a reverse pattern of myositis ossificans. In essence, any of 
the microscopic patterns of high-grade intraosseous osteosarcoma may be seen in EO.  
The differential diagnosis should always include spindle cell (sarcomatoid) carcinomas and 
the exclusion of metastasis from a primary osteosarcoma, as well as carcinosarcomas, 
malignant tumours with osseous metaplasia and sarcomas. Metaplastic ossification, ranging 
from osteoid to woven bone formation can be seen in synovial sarcoma, epithelioid sarcoma, 
liposarcoma and carcinosarcoma. Osteogenic differentiation can also be seen as a phenomenon 
of dedifferentiation in various soft tissue sarcomas. In the above tumours, other histologic 
lineages or histologic characteristics of original tumours are usually present. The key to 
diagnosis, is the identification of the matrix surrounding the tumour cells and lack of epithelial 
differentiation. Furthermore, except osteoblastic, chondroblastic and fibroblastic 
differentiation, no other lineages of histologic differentiation should be detectable in EOs. 
Diagnostic confirmation using immunohistochemical markers is necessary to ensure the 
absence of an epithelial component and exclude the neoplasms of biphasic origin. 
Immunohistochemical studies indicate that the EOs’ immunophenotype is similar to bone 
osteosarcoma. EOs are uniformly positive for vimentin, they express smooth muscle actin 
(68%), desmin (25%), S-100 protein (20%), including non-cartilaginous areas, EMA (52%), 
Keratin (8%) and are negative for PLAP. 
Differential diagnosis from recurrent or metastatic osteosarcoma is based on clinical history. 
3. The use of cytology in the preoperative investigation of bone tumours with 
emphasis in osteosarcoma 
Fine needle aspiration (FNA) of bone lesions has been performed ever since the technique 
was introduced (Coley et al, 1931). It has certain advantages over open biopsy, as it is less 
disruptive to bone and permits multiple sampling without complications. Its main use is to 
confirm malignancy. Although, cytomorphology of primary bone tumours has been 
extensively described in correlation with histology (Hajdu, 1975; Stormby & Akerman, 
1973Walaas &Kindblom, 1990; White et al, 1988), FNA is not as good for diagnosing primary 
bone tumours. 
There are two main indications of FNA of soft tissue and bone lesions: preoperative 
diagnosis before definitive treatment and the investigation of lesions suspicious of tumour 
recurrence or metastasis. Eventhough, the first use has limitations, however, at present, the 
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use of FNA as the diagnostic, pre-treatment tool for musculoskeletal tumours is accepted in 
many orthopaedic centres, provided that certain requirements are fulfilled and that the final 
cytologic diagnosis is based on the combined evaluation of clinical data, radiographic 
findings and cytomorphology (Domansky et al, 2010). One important reason, why FNA is 
preferred upon open biopsy, is when the preoperative evaluation of a lesion as malignant is 
of most importance, rather the subtype of the lesion. On the other hand, in the use of neo-
adjuvant treatment (radio- or chemotherapy), before surgery, the FNA diagnosis is of major 
importance, analogous to histopathologic examination, in regard to subtype and tumour 
grade. This is mostly the case with small round cell sarcomas. Regarding bone lesions, FNA 
may also replace open biopsy in the primary diagnosis. It is the task of the pathologist to 
distinguish benign and malignant primary bone tumours from metastatic deposits and from 
the wide range of benign and inflammatory reactive lesions of the bone. Furthermore, the 
pathologist should give a confident diagnosis of the various benign bone tumours and 
sarcomas, if open biopsy is to be avoided. Skeletal aspiration is not different from other 
aspirations, but it is important to remember that intact cortical bone cannot be penetrated by 
regularly used (22 gauge) needles, something that can be easily done with partly destroyed or 
eroded bone. A 18-gauge needle can be used in intact bone, under anaesthesia and multiple 
passes can be performed. Many malignant bone tumours have palpable soft tissue 
involvement, which can be much easier penetrated by the needle. In any case, it is strongly 
recommended that the pathologist is familiar with the radiological findings, discuss the best 
approach to the tumour with the radiologist and that non-palpable lesions are aspirated under 
image-guided techniques. Essentially, when the aspirated material is technically satisfactory, it 
is suitable for use of specialized techniques, likewise biopsy material, to assist in the diagnosis. 
The FNA cytological findings of osteosarcoma have thoroughly been described (Mertens et 
al, 1982; Walaas &Kindblom, 1990; White et al, 1988). They include mixture of cell clusters 
and dispersed cells, pleomorphic, spindle and rounded cells with frequent mitoses, 
including atypical forms, intercellular tumour matrix of osteoid, benign osteoclast-like giant 
cells, epithelioid tumour cells, which may be of osteoblastic type, or resemble chondroblasts, 
in osteoblastic and chondroblastic variants respectively, atypical spindle-shaped cells in 
fibroblastic subtypes. The presence of osteoid-like material can be ‘prominent, or scarce, 
dissociated, or in association with cell clusters, either as moderate-sized fragments, or not 
easily discernible globule-like particles’. This material could be associated either with the 
predominat histologic pattern or with the sampled area represented in the smears. Osteoid-
like matrix material has been originally described as ‘homogeneous or vacuolated 
eosinophilic plaques’ or pink-purple acellular material in May Grunwald Giemsa (MGG) 
smears and green-blue in Papanicolaou-stained (PAP) smears. Another cause of difficulty in 
accurately assessing the presence of osteoid in the smears is that osteoid, cartilage and dense 
collagen fibers appear very similar in both Diff-Quick and PAP stains. Furthermore, osteoid 
resists the suction, during aspiration, and when aspirated, the small, disrupted fragments 
lack the characteristic lattice-like pattern observed in histological sections (Mertens & 
Langnickel, 1982; Nikol et al, 1998). 
FNA has proven to be of value in the preoperative diagnosis of breast EOs (Trihia et al, 2007). 
Its diagnosis is often delayed because of a desceptively benign clinical and radiologic 
appearance (Watt et al, 1984). Although differential diagnosis from metaplastic carcinoma may 
not be possible on cytological grounds alone, FNA has proven to be of value in preoperative 
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diagnosis of malignancy and prompt surgical intervention, as clinically and mammographically 
these lesions can be underdiagnosed as a benign tumour (Trihia et al, 2007). 
4. The role of immunohistochemistry in the diagnosis of osteosarcoma 
The diagnostic algorithm of primary bone tumors is, and always has been, a collaborative 
effort in which clinical, radiologic, and pathologic findings have to be considered. In the 
majority of cases, the pathologist can rely exclusively on histopathologic examination to 
provide an accurate diagnosis. In some cases, however, ancillary studies have to be 
employed to distinguish entities that share morphologic characteristics.  
When evaluating a bone tumor, the pathologist is confronted with several difficulties. Bone 
tumors are rare entities, and not all pathologists are exposed to bone pathology with the 
frequency needed to gain the necessary level of diagnostic expertise. Also, certain osseous 
tumors share histopathologic features and, in many cases, important diagnostic features 
may not be readily evident in small specimens. Finally, intramedullary lesions often must be 
decalcified, a process that may be associated with loss in cellular morphologic detail. All of 
these factors complicate the diagnostic process. Diagnosis for many entities can be reached 
by the evaluation of histopathologic features alone, or can be interpretated in the context of 
clinico-radiologic findings, but for others, only a differential diagnosis can be reached 
without ancillary studies.  
Several studies have shown that gentle decalcification methods preserve antigenicity 
relatively well for the most commonly used markers.  
One of the greatest challenges in bone and soft tissue pathology is the reliable recognition of 
osseous matrix production in malignant lesions. Although several antigens have been 
explored, unfortunately, little is known about the antigenic specificity of normal bone tissue 
and bone neoplasms and currently there is no specific marker to distinguish the bone matrix 
from its collagenous mimics. 
Since late 1990’s, due to their central function in the process of mineralization, a group of 
proteins have been proposed for tumor diagnosis: alkaline phosphatase, osteonectin, and 
osteocalcin. Osteocalcin (OCN) and osteonectin (ONN) have been applied to paraffin 
sections and been used to highlight osteoid. OCN is one of the most prevalent intraosseous 
proteins and is produced exclusively by bone-forming cells-osteoblasts and therefore has 
received special attention as a specific marker (Fanburg et al, 1997, 1999; Takada et al, 1992). 
In the detection of bone-forming tumors, osteocalcin has been associated with 70% 
sensitivity and 100% specificity, compared with the 90% sensitivity and 54% specificity 
reported for ONN. Nevertheless, OCN is rarely used in clinical practice. ONN is a protein 
that is implicated in regulating the adhesion of osteoblasts and platelets to their extracellular 
matrix, as well as early mineralization and should only be used as part of a panel of 
reagents, directed at several lineage-related proteins (Serra et al, 1992; Wuisman et al, 1992). 
Strong labeling of the osseous isozyme of alkaline phosphatase has been used to distinguish 
EO from other pleomorphic sarcomas. The major drawback of this marker is that it can only 
be used on cryostat sections and imprint smears. 
Ancillary techniques have a limited role in diagnosing osteosarcoma, as the tumour is 
largely recognized by its morphologic features. Because of the many varieties of 
osteosarcoma, diverse tumours are considered in its differential diagnosis. 
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Currently, immunohistochemistry has limited application in the differential diagnosis of 
primary bone tumors. In general, osteosarcoma has a broad immunoprofile that lacks 
diagnostic specificity. Vimentin, OCN, ONN, S-100 protein, muscle protein smooth muscle 
actin (SMA), neuron specific enolase (NSE) and CD99 are some of the antigens that are 
commonly expressed. Importantly, some tumours also stain with antibodies to keratin and 
epithelial membrane antigen (EMA). Also, it’s worth noticing, that osteosarcoma usually 
does not stain with antibodies to factor VIII and CD31. 
Osteosarcoma is distinguished from benign tumours and fibro-osseous lesions, by virtue of 
its infiltrative growth pattern, with the tumour replacing the marrow space and 
surrounding bony trabeculae, which may also serve as scaffolding for the deposition of 
neoplastic bone. 
Telangiectatic osteosarcoma differs from aneurysmal bone cyst because it contains 
cytologically malignant cells within the cyst walls, whereas the cells in aneurysmal bone 
cyst are banal in appearance. 
Biopsies of osteosarcoma that lack neoplastic bone can be problematic because its 
immunophenotype can generate a broad list of differential diagnoses that include Ewing’s 
sarcoma/Primitive Neuroectodermal Tumour-PNET, metastatic carcinoma and melanoma, 
leiomyosarcoma and malignant peripheral nerve sheath tumour. 
The subtype of osteosarcoma that most likely will benefit from the application of an 
immunohistochemistry panel is the "small-cell" type. The diagnosis of this entity is difficult 
due to the paucity of osteoid and the similarity to other small round-cell tumors. Although 
the antigenic profile of small-cell osteosarcoma is unknown, expression of markers specific 
for other small-cell tumors, help in ruling out this diagnosis.  
In these circumstances, immunohistochemical analysis, electron microscopic evaluation and 
molecular studies may be helpful. Small cell osteosarcoma is distinguished from Ewing’s 
sarcoma by the presence of neoplastic bone and dilated rough endoplasmic reticulum by 
electron microscopy, as osteosarcoma cells have the features of mesenchymal cells with 
abundant endoplasmic reticulum and the matrix contains collagen fibres, which may show 
calcium hydroapatite crystal deposition and the absence of t(11;22) translocation, or its 
variants, which is diagnostic of Ewing’s sarcoma.  
MIC-2 gene product (CD99), which is located in the short arm of the sex chromosome, 
encodes a surface protein, first described in T-cell and null-cell acute lymphoblastic 
leukemia. Osteosarcoma usually has a diffuse moderate to strong intracytoplasmic staining 
for CD99. Tumour cells of the small cell variant of osteosarcoma may be positive for CD99, 
vimentin, osteocalcin, osteonectin, smooth muscle actin, Leu-7 and KP1. 
The differential diagnosis of osteosarcoma from other sarcomas (e.g., malignant fibrous 
histiocytoma, fibrosarcoma) is important because of the specific therapy available for 
osteosarcoma patients. Most osteosarcomas express vimentin and, according to some 
authors, some tumors focally express cytokeratin and desmin, although these findings have 
not been widely confirmed. Bone matrix proteins, such as OCN, alkaline phosphatase, and 
ONN, are expressed in osteosarcomas. However, their presence has also been detected in 
chondrosarcomas, Ewing’s sarcoma, fibrosarcomas, and malignant fibrous histiocytomas. 
Caution should also be used in the interpretation of focal expression of a variety of markers 
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(e.g., S-100, actin, epithelial membrane antigen) found occasionally in otherwise typical 
osteosarcomas. Extraskeletal osteosarcomas of the fibroblastic subtype often have sparse 
amounts of osteoid and can be differentiated from malignant fibrous histiocytoma on the 
basis of strong expression of alkaline phosphatase. Chondroblastic osteosarcoma and 
chondrosarcoma, however, cannot be distinguished immunohistochemically.  
The different types of collagen present in the bone matrix are also produced by other tumors 
and therefore have no application in differential diagnosis. The basic calponin gene, a 
smooth muscle differentiation-specific gene that encodes an actin-binding protein involved 
in the regulation of smooth muscle contractility, is expressed in osteosarcomas (Yamamura, 
et al, 1998). 
The list of entities included in the differential diagnosis of MFH is extensive. 
Immunohistochemistry helps in the distinction of MFH (CD68+, OCN-, alkaline 
phosphatase-) from leiomyosarcoma (CD68-), malignant neurilemmoma (S-100+) and from 
fibroblastic osteosarcoma (occasionally positive for both OCN, alkaline phosphatase). The 
distinction of cytokeratin-positive MFH from sarcomatoid carcinoma may be impossible by 
immunohistochemistry and is best accomplished by electron microscopy.  
Finally, stress fracture and accompanying callus can sometimes be confused with 
osteosarcoma because the reactive bone and cartilage are deposited around pre-existing 
bony trabeculae, mimicking an infiltrative pattern of growth. However, the cells in reactive 
tissues are banal and osteoblastic rimming is usually present. 
In conclusion, although immunohistochemistry does not currently play an important 
diagnostic role in primary bone tumors as it does in soft-tissue counterparts, research efforts 
to characterize the histogenesis of many of these neoplasias may offer new alternatives for 
diagnosis in the near future. For the distinction of primary tumors versus metastases of non-
osseous origin and for the characterization of a small subset of neoplasias, such as those 
with small round-cell morphology, immunohistochemistry remains the technique of choice.  
5. Molecular pathology of osteosarcoma 
Traditionally, our understanding of osteosarcoma has been largely based on anatomic and 
histologic features. However, recent studies in the molecular pathology of osteosarcoma 
have provided new insight into its pathogenesis. Through the identification of molecular 
pathways of osteosarcoma development and progression, the roles played by mutated 
tumor suppressor genes, oncogenes, and cell cycle regulatory molecules in bone 
oncogenesis, differentiation, cell death and cell migration have been explored. Furthermore, 
numerous cytogenetic abnormalities have been associated with osteosarcoma, including 
chromosomal amplifications, deletions, rearrangements, and translocations. 
Thus, the diagnostic and prognostic significance of molecular aberrations are beginning to 
be evaluated and novel approaches for therapeutic interventions of osteosarcoma are being 
developed. 
5.1 Bone growth, differentiation and osteosarcoma tumorigenesis 
It is well known that osteosarcoma has a propensity for developing in bone growth plates 
characterized by rapid bone turnover during childhood and adolescence (Broadhead et al., 
2011; Gelberg et al., 1997)   
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Additionally, patients affected by Paget’s disease, a disorder characterized by both excessive 
bone formation and breakdown, also have a higher incidence of osteosarcoma (Vigorita, 
2008). These observations, along with the knowledge that normal bone differentiation 
process occurs in the epiphyseal growth plates, strongly suggest that osteosarcoma is caused 
by genetic and epigenetic disturbances in the osteoblast proliferation and differentiation 
pathways (Tang et al., 2008; Thomas et al., 2006). 
Osteogenesis results from a regulated sequence of events involving epithelial mesenchymal 
interactions, condensation, and terminal differentiation. Several major signal transduction 
pathways, such as Wnt, BMP, FGF, and hedgehog signaling, play an important role in 
regulating osteogenic differentiation (Glass & Karsenty, 2007; Luu et al., 2007; Reya 
&Clevers, 2005). Bone lineage commitment and terminal differentiation are regulated by 
several osteogenic transcriptional factors such as, Runx2, Osterix, ATF4, and TAZ (Chien & 
Karsenty, 2005; Deng et al., 2008;  Kansara & Thomas, 2007; Karsenty, 2000; Karsenty, 2002;  
Karsenty, 2003; Hong et al., 2005; Yang & Karsenty, 2004) in coordination with their 
activators, like Rb which transactivates Runx2 (Ogasawara et al., 2004; Thomas et al., 2001) 
and their repressors, like WWOX which suppresses RUNX2 transcriptional activity (Del 
Mare et al., 2011). 
Among these factors, Runx2 is the most important regulator of bone development and 
serves as a hub to direct progenitors to osteogenic lineage through BMP-induced 
osteogenesis, synergistically inducing many terminal differentiation markers  (Lian et al., 
2006; Nakashima et al., 2002; Thomas et al., 2004; Yamaguchi et al., 2000). Additionally, 
Runx2 associates with p27KIP1 protein and through interaction with  the 
hypophosphorylated form of Rb and transactivation of Osterix transcription factor, 
promotes terminal cell cycle exit and the formation of a differentiated osteoblastic 
phenotype (Nakashima et al., 2002; Nishio et al., 2006; Thomas et al., 2004). 
Furthermore, the canonical Wnt pathway has been identified to play a crucial role in 
osteoblast differentiation, as evidenced by the fact that Wnt3a expression leads to cell 
proliferation and suppression of osteogenic differentiation in adult mesenchymal stem cells 
(Boland et al., 2004), and that multiple aberrations in the Wnt signaling pathway have been 
associated with osteosarcoma tumorigenesis (Haydon et al., 2002, Reya & Clevers, 2005, 
Clevers, 2006). 
Disruption of the well–coordinated balance between osteogenic progenitors proliferation 
and differentiation may lead to osteosarcoma development. The defects caused by genetic 
(eg, activation of oncogenes or inactivation of p53 and RB tumor suppressor genes) and 
epigenetic alterations may occur at different stages of osteogenic differentiation leading to 
more or less aggressive tumorigenic phenotypes (Kansara and Thomas, 2007). 
Moreover, osteosarcoma cells utilize an alternative lengthening of telomere (ALT) pathway 
that prevents telomere shortening, allowing the tumor cells to evade senescence and 
resemble their stem cell progenitors (Wang, 2005). 
5.2 Osteosarcoma invasion and metastasis 
Osteosarcoma is an aggressive tumor with high metastatic potential. Osteosarcoma invasion of 
bone and metastasis to other organs relies on complex cell-cell and cell-matrix interactions. The 
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invasion and metastatic sequence involves the detachment of osteosarcoma cells from the 
primary site, lysis of bone matrix, local migration, invasion through stromal tissue, 
intravasation, and extravasation. In this process, interactions between osteosarcoma cells, 
osteoblasts and osteoclasts are the main events leading to the substantial osteolysis exhibited 
by some osteosarcomas  as a result of increased osteoclastic activity.  
During the initial stages of osteosarcoma invasion, TGF-ǃ is released from the degraded 
bone matrix and acts on osteosarcoma cells, stimulating the release of PTHrP, interleukin-6 
(IL-6) and interleukin-11 (IL-11) (Quinn et al., 2001). These cytokines then stimulate 
osteoclasts, facilitating further invasion and release of proresorptive cytokines. Osteoblasts 
function as mediators in this process of bone resorption. Osteosarcoma cells release 
endothelin-1 (ET-1), VEGF, and PDGF in response to the hypoxic and acidotic conditions 
leading to angiogenesis and stimulation of  osteoblastic function (Kingsley et al., 2007; 
Chirgwin et al., 2007). PTHrP and IL-11 also act on osteoblasts, stimulating increased 
expression of receptor activator of nuclear factor κB ligand (RANKL). RANKL is a main 
mediator of osteoclast differentiation and activity, and osteosarcoma cells produce RANKL 
independently (Kinpara, 2000). RANKL activates osteoclasts through binding to RANK on 
the osteoclast surface. RANK expression is regulated by cytokines IL-1, IL-6, IL-8, tumour 
necrosis factor-ǂ (TNF-ǂ), PTHrP, and TGF-ǂ (Hofbauer & Heufelder, 1998). 
Receptor-ligand binding leads to activation of both NFκB and MAPK pathways, with a 
resulting increase in nuclear factor of activated T cells (NFATc1) activity. RANK/RANKL 
also activates the c-Fos component of AP-1, resulting in additional NFATc1 upregulation. 
NFATc1 then activates the transcription of genes involved in osteoclast activity and 
maturation (Takayanagi, 2007). 
Activated osteoclasts release proteases such as cathepsin K (Cat K) necessary for breakdown 
of collagen I, osteopontin, and osteonectin (Stoch & Wagner, 2008) aiding the invasion 
process (LeGall et al., 2007). This protease is essential for osteoclast function in normal bone 
remodelling and also in pathological states of osteolysis. For patients with high-grade 
metastatic osteosarcoma, low Cat K levels at the time of diagnosis confers a better prognosis 
(Husmann et al., 2008). 
Invasion of the surrounding tissues by osteosarcoma also involves degradation of the 
extracellular matrix. Matrix metalloproteinases (MMPs) are principally involved in the 
breakdown of the extracellular matrix and are regulated by natural inhibitors such as tissue 
inhibitors of MMPs (TIMPs), RECK, and ǂ2 macroglobulin  (Birkedal-Hansen et al., 1993; 
Chakraborti et al., 2003). In the setting of osteosarcoma, MMPs break down extracellular 
collagens, facilitating both tumour and endothelial cell invasion. MMPs play also a role in 
angiogenesis aiding further the metastatic process.  
The urokinase plasminogen activator (uPA) and its receptor (uPAR) system is another key 
regulator of osteosarcoma invasion, which acts as an activator of pro-MMPs. An inverse 
relationship between uPA levels and overall survival  has been demonstrated in 
osteosarcoma cases (Choong et al., 1996). 
5.3 Syndromes associated with osteosarcoma 
A variety of genetically based diseases and syndromes show a susceptibility to the 
development of osteosarcoma, such as Paget’s disease, Rothmund-Thomson, Bloom,Werner 
and Li-Fraumeni syndromes, as well as Hereditary Retinoblastoma. 
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In patients affected by Paget’s, a hereditary disorder characterized by rapid bone 
remodelling leading to dysregulated  bone turnover,  about 1 % of them will develop 
osteosarcoma. This percentage accounts for a substantial fraction of the osteosarcoma cases 
diagnosed over 60 years of age (McNairm et al., 2001). Although the complete pattern of 
genetic aberrations  leading to Paget’s disease remains unclear, LOH18CRI  located at 18q21-
q22 locus has been identified as the major underlying genetic abnormality linked to Paget 
osteosarcoma (Cody et al., 1997; Good et al., 2002; Hansen et al.,1999; Nelissery et al., 1998 ). 
Furthermore, the genes SQSTMI at 5q31 and  MAPK8 at 5q35qter,  which are implicated in 
IL-1/TNF and RANK signalling pathways,  respectively, seem to be involved in Paget 
osteosarcoma pathogenesis (Kansara & Thomas, 2007). 
Rothmund-Thomson, Bloom and Werner syndromes are characterized by germline 
mutations in RecQ helicases genes whose products  are responsible for separation of double-
stranded DNA prior to replication (German, 1993; Goto et al., 1996; Hickson, 2003). Among 
them Rothmund-Thomson syndrome, an autosomal recessive disorder, is related to the 
highest osteosarcoma incidence (32 %) with a tendency to occur at a younger age (Tang et 
al., 2008; Wang, 2001; Wang et al, 2003; Wang et al., 2005). 
Li-Fraumeni syndrome patients are characterized by germline mutations in p53 gene and  
have an increasesd risk in developing osteosarcomas among other malignancies (Malkin et 
al., 1990). 
Hereditary Retinoblastoma patients have germline mutations in Rb1 tumor suppressor gene 
and  are predisposed to develop osteosarcoma (Araki et al., 1991). Such bone sarcomas are 
likely to show LOH at 13q and molecular alterations of the Rb1 gene (Andreassen et al., 
1993; Wadayama et al., 1994; Wunder et al., 1991). 
5.4 Cytogenetic aberrations  
5.4.1 Conventional osteosarcoma 
5.4.1.1 Cytogenetics 
Although the germline mutations explain part of the osteosarcoma cases, most 
osteosarcomas are sporadic. Sporadic osteosarcomas have  a wide range of genetic 
abnormalities and display extensive genetic heterogeneity. However  involvement of certain 
chromosomal loci is recurrent and chromosomal regions 1p11-13, 1q11-12, 1q21-22, 11p14-
15, 14p11-13, 15p11-13, 17p and 19q13 are most frequently affected (Mertens et al., 1993; 
Tarkkanen et al., 1993). Numerical chromosomal abnormalities associated with conventional 
osteosarcoma include loss of chromosomes  6q, 9, 10, 13, and 17 as well as gain of 
chromosome 1 (Boehm et al., 2000; Bridge et al., 1997; Stock et al., 2000). 
Recent studies have identified amplifications of chromosomes 6p21, 8q24, and 12q14, as well 
as loss of heterozygosity of 10q21.1, as being among the most common genomic alterations 
in osteosarcoma. Furthermore,  patients carrying these aberrations  had a poorer prognosis 
(Smida et al., 2010).  
Cytogenetic features  of gene amplification, such as ring chromosomes, double minutes, and 
homogeneously staining regions are frequently identified in conventional osteosarcomas 
(Menghi-Sartorio et al., 2001). 
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Despite intensive research, no consensus specific chromosomal aberrations that could be 
used diagnostically in  osteosarcoma tumors have been identified.  
5.4.1.2 DNA copy numbers 
Osteosarcoma tumors contain multiple random chromosomal aberrations and only a few 
deletions and amplifications appear common to comparative genomic hybridization (CGH) 
studies (Atiye et al., 2005; Selvarajah et al., 2008). 
Comparative genomic hybridization analysis reveals that chromosomal regions 3q26, 4q12-
13, 5p13-14, 7q31-32, 8q21-23, 12q12-13, 12q14-15, and 17p11-12 are most frequently gained 
(Menghi-sartorio et al., 2001; Stock et al., 2000; Tarkannen et al., 1995). Gain of 8q23 is 
detected  in 50% of tumors (Stock et al., 2000) and is correlated with poor prognosis 
(Tarkkanen et al., 1989). Increased copy number of the MYC gene localized to 8q24 was 
detected by in situ hybridization in 44% of cases (Stock et al., 2000). The most frequent losses 
are found at 2q, 6q, 8p, and 10p (Knutila et al., 2000; Tarkannen et al., 1995). 
In a recent study with 10 osteosarcomas, CGH whole-genome analysis showed changes 
including: hypomethylation, gain, and overexpression of histone cluster 2 genes at 
chromosome 1q21.1-q21.3; loss of chromosome 8p21.2-p21.3 and underexpression of 
DOCK5 and TNFRSF10A/D genes; and amplification-related overexpression of  RUNX2 at 
chromosome 6p12.3-p21.1. Amplification and overexpression of RUNX2 could disrupt 
G2/M cell cycle checkpoints and bone differentiation leading to genomic instability. 
Disruption of DOCK5-signaling, together with p53 and TNFRSF10A/D related cell cycle 
and death pathways, may play a critical role in abrogating apoptosis (Sadicovic et al., 2009). 
Diploid ploidy pattern by DNA fluocytometry has been reported to be a poor prognostic 
sign (Kusuzaki et al., 1999). 
5.4.1.3 Loss of heterozygosity (LOH) 
Loss of heterozygocity are detected more frequently at the long arms of chromosomes 3, 13 
and 18 and at the short arm of chromosome 17 (Kruzelock et al., 1997). As the incidence of 
LOH is high at 3q26.6-26.3, this area has been suggested to harbour a putative suppressor 
gene (Kruzelock et al., 1997). 
5.4.2 Telangiectatic osteosarcoma 
A limited number of cases show highly complex chromosomal changes, and only one case is 
characterized by trisomy 3 (Bridge et al., 1997; Fletcher et al., 1994; Hoogerwerf et al., 1994). 
Mutations in the TP53 and RAS genes, LOH at the TP53, CDKN2A and RB1 loci, and 
amplification of the MDM2 and MYC genes are rare in telangiectatic osteosarcomas (Radig 
et al., 1998). 
Telangiectatic osteosarcoma can be distinguished from aneurysmal bone cyst by the 
balanced tranlocations between the short arm of chromosome 17 and the long arm of 
chromosome 16 (Panoutsakopoulos  et al., 1999). This rearrangement is characteristic of 
aneurysmal bone cyst. However, there are many variations on this theme, and at least five 
different chromosomes can serve as translocation partners with chromosome 17 (Dal Cin et 
al., 2000; Herens et al., 2001; Wyatt-Ashmead et al., 2001). 
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5.4.3 Small cell osteosarcoma 
No specific cytogenetic abnormalities have been detected in small cell osteosarcoma. 
Small cell osteosarcoma can be distinguished from Ewing sarcoma by the presence of 
neoplastic bone and the absence of the t(11:22) translocation or one of  its variants. 
5.4.4 Low grade central osteosarcoma 
Low grade central (intramedullary) osteosarcoma show minimal chromosomal imbalances 
compared with the complex cytogenetic aberrations identified in high grade osteosarcoma. 
Cytogenetic studies revealed ring chromosomes of amplified regions 12q13-15, as well as 
abnormalities in chromosome 6p, 14 and 15 (Werner et al., 1998). 
Comparative genomic hybridization demonstrate recurrent gains in chromosomal regions at 
12q13-14, 12p, and 6p21 (Tarkkanen et al., 1998). MDM2, CDK4, and SAS at the 12q13-15 
amplicon have been reported to be amplified at frequencies of 35%, 65% and 15%, 
respectively (Ragazzini et al., 1999). 
5.4.5 Postradiation osteosarcoma 
Cytogenetic and DNA copy number changes are complex and similar to those in 
conventional osteosarcomas (Mertens et al.; 2000). Postradiation osteosarcomas frequently 
exhibit 3p and 1p chromosomal losses compared to sporadic osteosarcoma which show 
more gains than losses (Mertens et al., 2000; Tarkkanen et al;, 2001). 
In one study, a high (58%) incidence of TP53 mutations was found (Nakanishi et al., 1998). 
5.4.6 Parosteal osteosarcoma 
Chromosomal alterations in parosteal osteosarcomas (low grade surface osteosarcomas) are 
characterized by one or more supernumerary ring chromosomes, often as the sole alteration 
(Mertens et al., 1993; Örndal et al., 1993; Sinovic et al., 1992). 
Comparative genomic hybridization studies indicate 12q13-15 amplified region in the 
chromosomal rings (Szymanska et al., 1996). The SAS, CDK4, and MDM2 genes are 
coamplified and overexpressed in the majority of cases (Wunder et al., 1999).  
Mutations in RB1 (Wadayama et al., 1994) or microsatellite instability (Tarkkanen et al., 
1996) have not been found to be present in parosteal osteosarcoma. 
5.4.7 Periosteal osteosarcoma 
Most of the periosteal osteosarcomas show complex karyotypic aberrations (Gisselsson et 
al., 1998; Hoogerwerf et al., 1994; Tarkkanen et al., 1993).  
5.4.8 Extraskeletal osteosarcomas 
Clonal chromosomal aberrations with complex patterns have been reported (Mandahl et al., 
1989; Mertens et al. 1998). So far, no genetic differences between osteosarcomas of bone and 
extraskeletal origin have been identified. 
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5.5 Molecular genetic alterations 
A number of molecular defects in tumor suppressor genes, oncogenes, bone differentiation 
genes and genes involved in cell migration have been observed in osteosarcomas. 
5.5.1 Tumor suppressor genes 
The p53 and retinoblastoma (Rb) genes are the major tumor-suppressor genes affected in 
osteosarcoma  (Marina et al., 2004).The p53 gene is mutated in 22% of osteosarcomas (Ta et 
al., 2009) and its expression seems to be higher  in low grade osteosarcomas and correlate 
with reduced metastatic disease and improved survival (Hu et al., 2010). p53 mutation has 
also been shown to be more common in high-grade conventional osteosarcomas versus low 
grade central osteosarcomas (Park et al., 2004). However, other studies showed no 
correlation between survival and the p53 protein, while coexpression of p53 and P-
glycoprotein was associated with a poorer prognosis (Lonardo et al., 1997; Park et al., 2001).  
In addition to p53, the Rb tumour suppressor has also been implicated in the tumorigenesis 
of osteosarcoma. Both germ-line and somatic mutations of Rb confer an increased risk of 
osteosarcoma (Benassi et al., 1999). Loss of heterozygosity for Rb has been reported to confer 
both an improved and poorer prognosis for patients (Heinsohn et al., 2007; Wadayama et al., 
1994; Feugeas et al., 1996). 
5.5.2 Oncogenes 
Transcription factors c-Fos and c-Jun are significantly upregulated in high-grade 
osteosarcomas compared with benign osteogenic lesions and low-grade osteosarcomas (Wu 
et al., 1990; Franchi et al., 1998) and are associated with the propensity to develop metastases 
(Gamberi et al., 1998). 
Another transcription factor involved in cell proliferation, is c-Myc, whose amplification has 
been implicated in osteosarcoma pathogenesis and resistance to chemotherapeutic drugs. 
Overexpression of Myc in bone marrow stromal cells leads to osteosarcoma development 
and loss of adipogenesis (Shimizu et al., 2010).  
Overexpression of MET (Ferracini et al., 1995; Rong et al., 1993) and c-Fos (Wu et al., 1990) 
has been reported in more than 50% of osteosarcoma cases, whereas c-Myc is overexpressed 
in less than 15% of cases (Barrios et al., 1993; Ladanyi et al., 1993). c-Myc, c-Fos, and 
cathepsin L have been shown to be overexpressed in a high proportion of relapsed tumours 
and metastases (Gamberi et al., 1998; Park et al., 1996). 
Transforming growth factor beta (TGF-ǃ) family proteins are also implicated in 
osteosarcomagenesis through impairment of osteoblast proliferation, differentiation and cell 
death. High-grade osteosarcomas are found to express TGF-ǃ1 in significantly higher 
amounts than low-grade osteosarcomas (Franchi et al., 1998). 
IGF (insulin-like growth factor)-I and IGF-II are growth factors that are often overexpressed 
by osteosarcomas (Rikkof et al., 2009). 
Connective tissue growth factor (CTGF) is related to a number of proteins in the CCN family 
(CTGF/Cyr61/ Cef10/NOVH). This protein family act via integrin signalling pathways 
(Lau et al., 1999) and, is involved in a diverse range of functions including adhesion, 
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migration, proliferation, survival, angiogenesis, and differentiation. A related protein, 
CCN3, was found to be overexpressed in osteosarcoma and associated with a worse 
prognosis (Perbal et al., 2008). 
In one study, a substantial percentage (42.6%) of osteosarcomas displayed high levels of 
HER2/neu (c-erbB2,ERBB2) expression, relative to adjacent normal tissues (Gorlick et al., 
1999).  
5.5.3 Genes amplifications 
Amplifications at 1q21-23 and at 17p are frequent findings in conventional osteosarcoma 
(Knuutila et al., 2000). Several genes have been reported to be involved in the 1q21-23 
amplicon (Forus et al., 1998; Meza-Zepeda et al., 2002). Similarly, a variety of genes in the 
12q13-15 region are co-amplified (Berner et al., 1997; Forus et al., 1994; Khatib et al., 1993; 
Momand et al., 1992; Oliner et al., 1992; Roberts et al., 1989; Smith et al., 1992; Yotov et al., 
1999).  
FISH analysis has revealed that genes, including CCND2, ETV6, and KRAS2, at 12p and 
MDM2 at 12q were differently amplified in low grade osteosarcomas (parosteal 
osteosarcoma) and high grade osteosarcomas (Gisselson et al., 2002). 
MDM2 (Ladanyi et al., 1993; Oliner et al., 1992) and PRIM1 (Yotov et al., 1999) 
amplifications have been detected in 14-27% and 41% of osteosarcoma cases, respectively. In 
aggressive osteosarcomas CDK4 is most consistently amplified, alone or together with 
MDM2 (Berneret al., 1996; Forus et al., 1994; Maelandsmoet al., 1995).  
Recently, it was shown that APEX1 gene was amplified in osteosarcomas and that APEX1 
expression was an independent predictor of the osteosarcoma local recurrence and/or 
metastasis (Yang et al., 2010). 
5.5.4 Gene expression 
Osteosarcoma cells share many similar features to undifferentiated osteoprogenitors, 
including a high proliferative capacity, resistance to anoikis, and expression of many 
osteogenic markers, such as CTGF, Runx2, ALP, Osterix, Osteocalcin and Osteopontin 
(Tang et al., 2008; Haydon et al., 2007; Luu et al., 2007). Furthermore, the more aggressive 
osteosarcoma  phenotypes often have features of early osteogenic progenitors, while less 
aggressive tumors seem to be more similar to osteogenic mesenchymal stem cells that 
have progressed further along the differentiation cascade (Broadhead et al., 2011; He et 
al., 2010). 
Osteogenic differentiation of mesenchymal stem cells can be monitored by using bone 
morphogenetic proteins (BMPs) and their downstream mediators, such as Id proteins and 
connective tissue growth factor (CTGF), as early markers, alkaline phosphatase and Osterix 
as early/middle markers and  osteocalcin and osteopontin as late markers of bone formation 
(Tang et al., 2008). 
Analysis of the expression of these osteogenic markers in osteosarcoma cells demonstrates a 
much lower alkaline phosphatase expression in tumor cells when compared to committed 
osteoblastic cell lines (Harris et al., 1995; Luo et al., 2008). Similarly, the late osteogenic 
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markers osteopontin and osteocalcin are highly expressed in mature, differentiated 
osteoblasts, but are minimally expressed in both primary OS tumors and OS cell lines 
(Cheng et al., 2003; Luu et al., 2007). CTGF, a multifunctional growth factor that is normally 
upregulated at the earliest stages of osteogenic differentiation, also shows elevated basal 
expression in human osteosarcoma cells (Luo et al., 2004). 
Recent studies have revealed that WWOX, a gene involved in bone differentiation, is deleted 
in 30% of osteosarcoma cases and WWOX protein is absent or reduced in ~60% of 
osteosarcoma tumors (Del Mare et al., 2011). WWOX associates with Runx2, a key regulator 
of bone differentiation. Interestingly, Runx2 has a very low expression in osteosarcoma cell 
lines. Runx2 also associates with BMPs, Rb, and p27KIP1 playing a crucial role in cell cycle 
and bone differentiation regulatory pathways. Thus, it is natural that any alterations would 
lead to uncontrolled proliferation and loss of differentiation. Accordingly, high-grade 
osteosarcomas show decreased expression of p27KIP1, while lower-grade tumors have 
detectable p27KIP1 levels (Thomas et al., 2004). 
Bone morphogenetic proteins (BMPs) such as bone morphogenetic protein-6 and bone 
morphogenetic protein receptor 2 are expressed in more than 50% of osteosarcomas and 
related to poor prognosis (Gobbi et al., 2002; Guo et al., 1999; Yoshikawa et al., 2004).  
As above mentioned, Wnt pathway plays a crucial role in osteoblast differentiation and 
elevated levels of ǃ-Catenin, an important regulator of the Wnt pathway, are correlated 
with osteoprogenitor proliferation and osteosarcoma metastasis (Iwaya et al., 2003). In 
addition, osteosarcoma tumors overexpressing LRP5, a Wnt co-receptor, are associated 
with a poorer prognosis and decreased patient survival (Hoang et al., 2004). Furthermore, 
Wnt mutations causing excessive Wnt (Wingless and int) signalling are associated to 
decreased survival and increased metastatic capacity (Hoang et al., 2004; Iwaya et al., 
2003; Kansara and Thomas, 2007). 
Other genes with altered expression associated to osteosarcoma include overexpression of 
MAGE genes  (Sudo et al., 1997), p19INK4D (a cyclin dependent kinase inhibitor involved in 
cell cycle regulation, found in 7 % of osteosarcomas) (Miller et al., 1997), transforming 
growth factor-beta (TGF┚) isoforms, of which TGF┚3 is strongly related to disease 
progression (Kloen et al., 1997) and vascular endothelial growth factor (VEGF, expression 
correlated with survival) (Jung et al., 2005). Antiangiogenic proteins such as 
thrombospondin 1, TGF-ǃ , troponin I, pigment epithelial-derived factor (PEDF), and 
reversion-inducing cysteine rich protein with Kazal motifs (RECK)  are downregulated in 
osteosarcoma (Ren et al., 2006; Cai et al., 2006; Clark et al., 2007). 
Overexpression of Ezrin, a protein involved in cell movement, correlates with poor outcome 
in paediatric osteosarcoma (Khanna et al., 2004) and according to animal studies, is 
overexpressed in highly metastatic osteosarcoma compared to tumors with lower metastatic 
potential (Khanna et al., 2000). 
MMP2 and MMP9 were overexpressed in osteosarcoma  cells and associated with the ability 
of the cells to metastasize (Bjornland et al., 2005). Increased expression of membrane-type 
MMP1 has been correlated with poor prognosis (Ushibori et al., 2006) and upregulation of 
TIMP1 is associated with poor clinical outcome  (Ferrari et al., 2004). 
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5.6 Epigenetics 
Compared to large number of studies describing genetic alterations in osteosarcoma, 
relatively few studies investigating epigenetic alterations have been reported so far (Benassi 
et al., 2001; Benassi et al., 1999; Harada et al., 2002; Hou et al., 2006; Thomas and Kansara, 
2006; Tsuchiya et al., 2000).  
Recent studies have identified  a close association between the aberrant methylation of 
histone cluster 2 genes, p14ARF/CDKN2A, p16 and Ras effector homologue (RASSF1A) 
genes and osteosarcoma tumorigenesis (Hou et al., 2006; Rao-Bindal & Kleinerman, 2011). It 
is believed that hypermethylation and subsequent transcriptional silencing of tumor 
suppressor genes contributes to the neoplastic process by increasing the mutation rate (Jones 
& Baylin, 2002; Wajed et al., 2001). 
5.7 Epilogue 
Understanding of the molecular pathogenesis of osteosarcoma has advanced considerably 
over recent decades. The processes involved in osteosarcoma oncogenesis have been 
outlined above with emphasis on the disruption of bone differentiation machinery. 
However, the study of pathogenic mechanisms is in itself not enough. Translational studies 
are critical if an effective treatment for osteosarcoma is to arise from this understanding of 
osteosarcoma molecular pathology. If osteosarcoma results from bone differentiation 
defects, future research should focus on identifying relevant biomarkers and therapies 
targeting cellular differentiation thereby avoiding complications associated with 
conventional chemotherapy and be most effective in treatment of this debilitating tumor. 
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